Ontology highlight
ABSTRACT:
SUBMITTER: Kumar SK
PROVIDER: S-EPMC4109061 | biostudies-literature | 2012 Jan
REPOSITORIES: biostudies-literature
Kumar S K SK Lee J H JH Lahuerta J J JJ Morgan G G Richardson P G PG Crowley J J Haessler J J Feather J J Hoering A A Moreau P P LeLeu X X Hulin C C Klein S K SK Sonneveld P P Siegel D D Bladé J J Goldschmidt H H Jagannath S S Miguel J S JS Orlowski R R Palumbo A A Sezer O O Rajkumar S V SV Durie B G M BG
Leukemia 20110729 1
Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2. The ...[more]